The British Pharmacopoeia: Setting standards that are trusted worldwide

Published 13 October

In this exclusive article between Citeline and Peter Crowley, Interim Secretary and Scientific Director of the BP Commission, you will discover how the BP is preparing for its landmark 2026 edition while strengthening its influence as a global bridge between science, regulation, and industry. Their coverage highlights the BP’s long-standing commitment to ensuring the quality, safety, and efficacy of medicines in the UK and globally.

In this article:

  • Understand how the BP’s alignment with the UK regulator, MHRA, streamlines global regulatory acceptance and market access
  • Learn how sustainability, digital tools, and inclusion are reshaping the way pharmaceutical standards are developed and delivered
  • Explore how the BP is supporting innovation in emerging areas like cell and gene therapy, biologics, and digital health
  • Gain insights into the BP’s evolving role in measuring patient impact and building trust across the life sciences ecosystem
Read now